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Pulse-Administered Toceranib Phosphate Plus Lomustine for
Treatment of Unresectable Mast Cell Tumors in Dogs
J.H. Burton, R.O. Venable, D.M. Vail, L.E. Williams, C.A. Clifford, S.M. Axiak-Bechtel, A.C. Avery,
and D.H. Thamm
Background: Nonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel
combination therapies is warranted. Intermittent administration of tyrosine kinase inhibitors (TKI) combined with cytotoxic
chemotherapy may effectively chemosensitize canine MCT while decreasing cost and adverse effects associated with either
agent administered as monotherapy.
Hypothesis/Objectives: The primary study objectives were to (1) identify the maximally tolerated dose (MTD), (2) deter-
mine the objective response rate (ORR) and (3) describe the adverse event profile of pulse-administered toceranib phosphate
(TOC) combined with lomustine.
Animals: Forty-seven client-owned dogs with measurable MCT.
Methods: Toceranib phosphate was given PO on days 1, 3 and 5 of a 21-day cycle at a target dosage of 2.75 mg/kg.
Lomustine was given PO on day 3 of each cycle at a starting dosage of 50 mg/m2. All dogs were concurrently treated with
diphenhydramine, omeprazole, and prednisone.
Results: The MTD of lomustine was established at 50 mg/m2 when combined with pulse-administered TOC; the dose-lim-
iting toxicity was neutropenia. Forty-one dogs treated at the MTD were evaluable for outcome assessment. The ORR was
46% (4 complete response, 15 partial response) and the overall median progression-free survival (PFS) was 53 days (1 to
>752 days). On multivariate analysis, variables significantly associated with improved PFS included response to treatment,
absence of metastasis, and no previous chemotherapy.
Conclusions and clinical importance: Combined treatment with pulse-administered TOC and lomustine generally is well
tolerated and may be a reasonable treatment option for dogs with unresectable or metastatic MCT.
Key words: Cancer; Chemotherapy; Dog; Tyrosine kinase inhibitor.
Mast cell tumors (MCT) are the most commoncutaneous tumors in the dog and are generally
successfully treated with wide surgical excision alone.1–3
Therapeutic challenges, however, arise with MCT that
are large or infiltrative, high grade, have metastasized
beyond the regional lymph node, or are located
where wide surgical excision is not possible. Several
medical treatments have been studied for MCT in
dogs, including corticosteroids alone, lomustine, chlor-
ambucil, hydroxyurea, and vinblastine as well as
various combinations of these agents.4–11 Although
generally well tolerated, response rates frequently
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Abbreviations:
ALT alanine transaminase
ALP alkaline phosphatase
CR complete response
DLT dose-limiting toxicity
ITD internal tandem duplication
MCT mast cell tumor
MTD maximally tolerated dose
ORR objective response rate
OS overall survival
PR partial response
PFS progression-free survival
PD progressive disease
RECIST response evaluation criteria in solid tumors
SD stable disease
TOC toceranib phosphate
TTMR time to maximal response
TKI tyrosine kinase inhibitor
VCOG-CTCAEVeterinary Co-operative Oncology Group – Common
Terminology Criteria for Adverse Events
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remain at or below 50% and usually are brief and
incomplete.4–12
The tyrosine kinase inhibitor (TKI), toceranib phos-
phate (TOC), has demonstrated single-agent antitumor
activity against MCT in dogs, but fewer than half of
the dogs with MCT experience objective tumor regres-
sion with only 14% experiencing complete responses
(CR).13 The TKI sunitinib and radiation therapy are
synergistic in preclinical models of pancreatic adenocar-
cinoma, soft tissue sarcoma, and breast cancer in
humans14–16 as well as between TOC and radiation
therapy in dogs with MCT.17 In addition, several stud-
ies have identified potentiation of the efficacy of paclit-
axel, doxorubicin, and vincristine by the TKI imatinib
in human preclinical models of KIT-positive melanoma
and Ewing’s sarcoma,18–20 presumably owing to down-
regulation of important antiapoptotic pathways. A
recent phase I study evaluating the safety of the combi-
nation vinblastine and TOC in dogs reported the neces-
sity for substantial dose reductions of vinblastine in this
combination therapy to prevent frequent and severe
neutropenia.21 Together, these data suggest that combi-
nation therapies with TKIs may improve efficacy over
single-agent treatments alone.
Clinically relevant adverse effects can be observed
with continuous long-term TKI administration, includ-
ing diarrhea, inappetence, neutropenia, proteinuria, fati-
gue, and musculoskeletal pain, resulting in the need for
drug holidays and dose reductions.13,22,23 Pulse adminis-
tration of TKIs with chemotherapy potentially may
chemosensitize tumor cells while decreasing cost and
toxicity associated with chronic TKI administration.
This phase I/II multicenter clinical trial sought to
determine the maximally tolerated dose (MTD), tolera-
bility and adverse event profile of combined treatment
with pulse-administered TOC, and lomustine in dogs
with measurable MCT. The second objective of this
study was to determine the objective response rate
(ORR), progression-free survival (PFS) and overall sur-
vival (OS) in dogs with measurable MCT treated with
combined pulse-administered TOC and lomustine, and
to identify potential prognostic factors in dogs treated
with this combination. We hypothesized that the combi-
nation of pulse-administered TOC and lomustine would
be well tolerated and efficacious when administered to
dogs with cutaneous MCT.
Materials and Methods
Patient Selection
Client-owned dogs with histologically or cytologically confirmed
MCT ≥10 mm in longest diameter, where surgical excision was not
feasible or was declined by the owner, were considered for enrol-
ment. Eligibility criteria included Veterinary Co-operative Oncol-
ogy Group – Common Terminology Criteria for Adverse Events
(VCOG-CTCAE) constitutional health score of 0 (normal activity)
or 1 (mildly decreased from baseline)24, and life expectancy of
>6 weeks. Dogs were required to have adequate hematologic,
renal, and hepatic function to safely undergo treatment; defined as
≥2,500 neutrophils/lL, ≥75,000 platelets/lL, PCV ≥28%, serum
creatinine concentration ≤29 the upper limit of normal (ULN),
total serum bilirubin concentration <1.59 ULN, alanine transami-
nase (ALT) activity ≤29 ULN, aspartate aminotransferase activity
≤29 ULN, and gamma-glutamyl transferase activity ≤29 ULN.
Dogs were excluded if they had other serious comorbid diseases or
had previously been treated with lomustine or any TKI. Prior sur-
gery was allowable as was radiation therapy or chemotherapy
(excluding previous treatment with lomustine or any TKI) with
6- and 2-weeks washout periods after radiation therapy and
chemotherapy, respectively.
Baseline evaluations included medical history, physical examina-
tion, abdominal ultrasound examination, cytologic evaluation of
regional lymph nodes, CBC, serum biochemistry, and urinalysis.
Thoracic radiographs were not required as part of the study but
were performed by some supervising clinicians as routine staging
for MCT. Tumor aspirates also were obtained at the time of
enrollment to assess for c-kit gene mutation. The participating
institutions’ Animal Care and Use Committees or Clinical Review
Boards approved the clinical protocol, and written informed con-
sent was obtained from the owners before patient enrollment.
Phase I Study Design and Treatment Protocol
Dogs were given diphenhydramine 2–4 mg/kg PO q12h, omep-
razole 0.7 mg/kg PO q24h, and prednisone 1 mg/kg PO q48h for
a minimum of 72 hours before the initiation of the treatment with
TOC; these medications were continued throughout the study per-
iod. An open-label, phase I, 3 + 3 dose-cohort escalation design
was employed to assess the safety of combination pulse-dosed
TOC and lomustine.25 All dogs were scheduled to receive TOC
2.75 mg/kg PO once on days 1, 3, and 5 of a 21-day cycle; the
TOC dose remained the same throughout the study and was given
on alternating days from the prednisone. Lomustine was adminis-
tered PO once on day 3 of the 21-day cycle; a starting dosage of
50 mg/m2 was selected for the initial cohort. The lomustine dose
was approximated to the nearest 10 mg using combinations of
commercially available 40 and 10 mg capsules.
Three dogs were enrolled in the first dose cohort and observed
for dose-limiting toxicities (DLT). A DLT was defined as any
grade 3 nonhematologic or grade 4 hematologic toxicity according
to the VCOG-CTCAE v1.0.26 If no DLTs were observed in the
first cohort of 3 dogs within 3 weeks of lomustine administration,
a second cohort was treated with the same dosage of TOC and an
increased dosage of lomustine. If a DLT was observed in 1 dog,
the cohort was expanded up to a total of 6 dogs. If no additional
DLTs were noted in the expanded cohort of 6 dogs, dose escala-
tion was continued with a higher dosage of lomustine. If ≥2 DLTs
were observed in the initial or expanded cohort, case accrual was
stopped and the MTD was determined to be the dosage used in
previous cohort where <2 DLTs were noted. Escalation of the lo-
mustine dosage was planned in 10 mg/m2 increments until the
MTD of the combination therapy was established.
Safety Evaluation
Dogs were evaluated 1 week after the first dose of lomustine
and a physical examination and CBC were performed. Reevalua-
tion occurred again 3 weeks after the lomustine dose; physical
examination, tumor measurements, CBC, and assessment of ALT
activity with or without other liver enzymes was performed at that
time. Owners completed a quality of life assessment form at each
study visit that has been previously described.27 Adverse events
noted on laboratory evaluation, physical examination, or noted by
owners were prospectively graded using VCOG-CTCAE v1.0.26
For dogs experiencing grade 3 or 4 neutropenia, a 20% dose
reduction of lomustine was performed for subsequent dosing
cycles. Increases in hepatic transaminase activity were managed at
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the discretion of the attending clinician with lomustine dose reduc-
tions, delays in treatment, or both. Either prophylactic or thera-
peutic treatment with hepatoprotectants was also allowable.
Antitumor Response Assessment
Once a MTD was identified, cohort expansion at the MTD was
performed according to a Simon’s Minimax design to evaluate the
efficacy of pulse-administered TOC and lomustine.28 Twenty-eight
dogs were to be enrolled in the first stage. If ≥11 of the 28 dogs
initially enrolled at the MTD experienced a tumor response, the
cohort was to be further expanded to include an additional 13
dogs to better define the response to treatment. If <11 of the 28
dogs experienced a response, enrollment would be discontinued.
Tumor response was assessed every 3 weeks in all dogs enrolled
in this study using modified Response Evaluation Criteria in Solid
Tumors (RECIST) criteria. The longest diameters of the target
lesions were documented before treatment initiation with TOC. A
CR was defined as the disappearance of all lesions, a partial
response (PR) was defined as at least a 30% decrease in the sum
of the target lesion diameters, and progressive disease (PD) was
defined as a ≥20% increase in the sum of the target lesion diame-
ters using baseline measurement as a reference. Stable disease (SD)
was defined as neither CR, PR, nor PD and must have persisted
for a minimum of 6 weeks. Dogs experiencing SD or PR were
given pulse-dosed TOC and lomustine once every 3 weeks until
disease progression. Dogs experiencing CR were treated with 5
cycles of the TOC/lomustine combination or 2 cycles beyond doc-
umentation of a clinical CR, whichever was longer, and were eval-
uated monthly after the last cycle of TOC/lomustine for tumor
response assessment. Dogs experiencing PD were removed from
the study.
c-Kit Mutation Status
Nucleic Acid Extraction. Genomic DNA samples were prepared
from Wright-Giemsa-stained fine needle aspirates. Slides were con-
firmed to have ≥10% of the cell population as mast cells. Qiagen
AL buffer was applied to the slides, which were then scraped with
a straight-edged razor into microcentrifuge tubes. DNA extraction
was then performed with a commercial kit according to the manu-
facturer’s instructions.a
PCR Amplification of c-kit Exons 8 and 11. Regions of c-kit
exons 8 and 11 were amplified with primers directed against
sequences flanking the characterized internal tandem duplications
(ITDs). The primer pair for exon 8 consisted of (TGACCTA
TGGCCATTTCTCT) coupled with (56FAM-AATCCTGCAA
CCACACACTG), resulting in a product of 92 bases. The pair for
exon 11 consisted of (CAGTGGAAGGTTGTTGAGGAG)
coupled with (VIC-CATGGAAAGCCCCTATTTCA), resulting in
a product of 132 bases. Amplifications were performed with a
commercially available PCR kit.b Primer concentrations used were
400 nM each.
Gene scanning analysis was performed using a capillary electro-
phoresis machine.c Amplified fragments were run with Gene
ScanTM-600 LIZ size standards. Raw data were analyzed with a
commercially available genotype analysis software.d
Statistics
Continuous data were expressed as median and range, and cate-
gorical data as frequencies and percentages. Time to maximal
response (TTMR) was calculated from the date of treatment initia-
tion to the date the best overall response was first documented.
Progression-free survival and OS were calculated from the date of
administration of the first dose of TOC to the date of PD or
death, respectively. Dogs that were still alive at the time of data
analysis were censored at the last date reported to be alive. Dogs
that had died were considered to be dead either secondary to their
treatment or their disease. Kaplan–Meier estimation was used to
estimate and display the distribution of the PFS and OS. Logrank
and Cox proportional hazards regression was used to evaluate
associations between patient and treatment factors and PFS and
OS. Simple regression was first used to determine which covariates
to include in the multiple regression model based on an alpha level
of 10%. Covariates with P-values < 0.10 in simple regression mod-
els were then included in multiple regression models. Multiple
regression models were estimated and covariates were removed in
a forward and reverse stepwise fashion because of insignificance at
the 5% alpha level. Variables with values of P ≤ 0.05 were consid-
ered significant. All statistical analyses were performed using com-
mercial software packages.e,f
Results
Patient Population
A total of 47 dogs were enrolled in the clinical trial
from March, 2011 to March, 2013; 13 were enrolled
into the dose escalation phase and the remainder into
the dose expansion phase. Dogs were enrolled at the
Flint Animal Cancer Center at Colorado State Univer-
sity (n = 28), North Carolina State University (n = 8),
University of Missouri (n = 5), University of Wiscon-
sin-Madison (n = 4) and Red Bank Veterinary Hospital
(n = 2). Patient demographics and tumor characteristics
for all dogs enrolled in phase 2 of the clinical trial are
described in Table 1.
Dose Escalation
The dose escalation cohorts are summarized in
Table 2. The MTD of lomustine when combined with
pulse-dosed TOC was determined to be 50 mg/m2.
Eight dogs were enrolled in the first cohort and given
lomustine at 50 mg/m2. One of the first 3 dogs enrolled
experienced a grade 4 neutropenia and 2 dogs subse-
quently enrolled were unable to be evaluated for safety
assessment, because they were withdrawn from the
study before day 7 because of progression of disease.
The lomustine dosage was increased to 60 mg/m2 in 2
dogs and both dogs in this cohort experienced grade 4
neutropenia. The dosage then was de-escalated to
55 mg/m2, at which 2 out of 3 dogs experienced grade 4
neutropenia.
Cohort Expansion and Outcome
Having established the MTD, an additional 20 dogs
were enrolled into the first phase of the clinical trial
cohort expansion and given TOC at the previously
described dosing schedule and lomustine at a target
dosage of 50 mg/m2 once every 3 weeks. Of the first 28
dogs treated with lomustine at 50 mg/m2 combined with
pulse-administered TOC, 13 dogs had an objective
tumor response (10 PR, 3 CR). Because the number of
dogs experiencing an objective tumor response was >11,
13 additional dogs were included in the dose expansion
phase of the study. This resulted in a total of 41 dogs
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evaluable for outcome evaluation at the MTD, because
1 dog was lost to follow-up 1 day after study com-
mencement. The median administered dosage of lomus-
tine was 47.6 mg/m2 (range 30.3–54.5 mg/m2) for a
median of 3 cycles (range 1–15 mg/m2). The median
administered dosage of TOC was 2.65 mg/kg (range
2.5–2.85 mg/kg). Hematologic adverse events were most
common with 34 dogs (82.9%) developing some degree
of neutropenia 1 week post-lomustine. Eight dogs
(19.5%) experienced grade 1 neutropenia, 10 (24.4%)
developed grade 2 neutropenia, 7 (17.1%) developed
grade 3 neutropenia and 9 (22%) experienced grade 4
neutropenia. Dose reductions were performed for 9
(22%) dogs experiencing neutropenia and no dose
delays were performed for management of neutropenia.
One dog developed grade 4 anemia which occurred at
the time visceral disease progression was noted. Hepato-
toxicity also was common, with 24 dogs (59%) develop-
ing increases in ALT activity; 9 dogs had severe
increases (8 grade 3 and 1 grade 4) in ALT activity.
Twelve (50%) dogs had increased ALT activity after 1
dose of lomustine and these increases generally were
mild (8 grade 1, 4 grade 2). Seven (29%) dogs devel-
oped increased ALT activity after 2 doses, 2 (8%) after
3 doses, and 1 (4%) developed increased ALT activity
after 5 doses of lomustine. Increased ALT activity was
associated with a lomustine dose decrease (grade 3,
n = 1) or dose delay (grade 1, n = 1; grade 2, n = 1;
grade 3, n = 5). In addition, 1 dog had grade 4
increased ALT activity and was removed from the
study. Hepatoprotectants were not administered pro-
phylactically in this study but were used in the manage-
ment of hepatotoxicity, with 13 dogs receiving
Denamaring after increases in ALT activity were iden-
tified. Adverse events are summarized in Table 3. In
summary, dose reductions of lomustine, treatment
delays or both were performed for 16 dogs (39%) to
manage adverse events in this study; these were imple-
mented at the discretion of the supervising clinician.
Seven dogs (17.1%) had a dose reduction of lomustine,
6 dogs (14.6%) had at least 1 treatment cycle delay,
and 3 dogs (7.3%) had both a dose reduction of lomus-
tine and a treatment delay performed. No dogs required
dose reductions or delays in TOC administration.
Fifteen dogs (36.6%) experienced PR and 4 dogs
(9.8%) experienced CR after lomustine and pulse-dose
TOC for an ORR of 46%. Of the remaining dogs, 6
had SD, 15 developed PD, and 1 dog was not evaluable
for response because of euthanasia by the primary care
veterinarian before response assessment. The presence
of a c-kit ITD was not associated with response to
treatment (P = 0.51). The median TTMR was 21 days
(range 7–175 days). The median PFS was 53 days
Table 2. Dose escalation cohorts.
Cohort
Toceranib
Dose (mg/kg)a
Lomustine
Dose (mg/m2)
Dogs
Treated
No. of Dogs
Experiencing
DLT
1 2.75 50 8b 1c
2 2.75 60 2 2c
3 2.75 55 3 2c
DLT, Dose-limiting toxicity.
aToceranib administered days 1, 3 and 5 of each cycle.
bTwo dogs were not evaluable for DLT assessment.
cAll dose-limiting adverse events were grade 4 neutropenia.
Table 3. Summary of adverse events (AE) occurring in
the dose expansion phase of the study (n = 40 dogs) as
defined by Veterinary Co-operative Oncology Group –
Common Terminology Criteria for Adverse Events v1.0
(2004).
Adverse Event
Grade
Category Term 1 2 3 4
Hematologic Neutropenia 8 10 7 9
Anemia 8 2 1 1
Thrombocytopenia 3 1
GI Vomiting 13 2
Diarrhea 7 4
Anorexia 6 2
Hepatic ALT elevation 7 8 8 1
Constitutional Lethargy 1 4
GI, Gastrointestinal; ALT, alanine aminotransferase.
Table 1. Patient demographics and tumor characteris-
tics for dogs enrolled in the dose expansion phase
(n = 41).
Median (Range) or Frequency (%)
Age (years) 8.2 (3.0–13.0)
Weight (kg) 28.2 (6.0–57.3)
Sex
MC 19 (46.3)
M 3 (7.3)
FS 17 (41.5)
F 2 (4.9)
Breed
Mixed breed 10 (24.4)
Boxer 10 (24.4)
Labrador retriever 7 (17.1)
Golden retriever 2 (4.9)
Pointer 2 (4.9)
Other (1 each) 10 (24.4)
Tumor dimension (cm) 6.7 (0.84*–21.8)
c-kit mutation status
Positive 15 (36.6)
Negative 23 (56.1)
Not evaluable 3 (7.3)
Prior treatment
Surgery 26 (63.4)
Chemotherapy 12 (29.3)
Radiation therapy 1 (2.4)
No prior treatment 2 (4.9)
Metastasis
None 10 (24.4)
Local lymph node 26 (63.4)
Distant  local node 5 (12.2)
*One dog initially had a tumor ≥1.0 cm that decreased after
3 days of prednisone before 1st cycle.
Pulse Toceranib Plus Lomustine 1101
(range 1 to >752 days) and the median OS was
131 days (range 4 to >752 days).
The median follow-up time in censored patients was
235 days. On univariate analysis, variables associated
with prolonged PFS included response to treatment
(Fig 1), absence of metastasis, no previous chemother-
apy, and smaller tumor diameter (<6.7 cm; Table 4).
The median PFS was not reached for dogs experiencing
CR, was 131.5 days for dogs experiencing PR, and was
77 days for dogs experiencing SD as their best response.
Variables associated with increased OS on univariate
analysis included no previous chemotherapy and smaller
tumor diameter (Table 5). The presence of a c-kit acti-
vating mutation was not associated with outcome
(P = 0.99 for PFS, P = 0.92 for OS). Variables that
remained significant upon multivariate analysis for
improved PFS included response, metastasis, and no
prior chemotherapy. Response to treatment, small
tumor diameter, and no prior treatment were associated
with a significantly improved OS (Table 6).
Discussion
Lomustine at 50 mg/m2 combined with pulse-admin-
istered TOC at 2.75 mg/kg can be safely administered
to dogs with MCT with a DLT of neutropenia. A lo-
mustine MTD of 50 mg/m2 once every 3 weeks when
combined with continuous dosing of TOC at 2.75 mg/
kg every other day recently was reported when
administered to dogs with tumors other than MCT;
the DLT in this phase I study with continuous TOC
administration also was neutropenia.29 Other common
adverse effects included hepatic and gastrointestinal
toxicities, which were not unexpected based on the
combination of drugs used in this protocol. Lomus-
tine is known to cause hepatotoxicity in dogs, with
reported rates of 83–86%.30–32 Twenty-four dogs
(59%) developed increases in ALT activity during this
study, with 9 dogs having grade 3 or 4 increases. The
incidence and severity of increased ALT activity was
less than previously reported, which may be due in
part to early intervention with hepatoprotectants, dose
delays, or both when mild increases in ALT activity
developed. The maximally tolerated dosage of lomus-
tine in this protocol was 50 mg/m2, which is 28.6–
44% lower than lomustine dosages reported elsewhere
for treatment of MCT.7–9 This decreased lomustine
dosage also may have decreased the frequency and
severity of hepatotoxicity observed in this study as
compared to previous studies. Dogs in this study also
were receiving prednisone concurrently with lomustine
and pulse-administered TOC, which routinely causes
increases in alkaline phosphatase (ALP) activity and
occasionally ALT as well.33 Some of the increased
ALT activity may have been due in part to predni-
sone administration. Because ALP activity was not
routinely evaluated throughout the study, it is not
possible to assess the influence of prednisone adminis-
tration on ALT activity.
Table 4. Factors evaluated for effects on progression-
free survival.
Groups n
Median
PFS
Logrank
P
Logrank HR
(95% CI)
Response CR/PR 19 169
SD/PD 21 42 <0.0001 3.496 (2.6–11.88)
Delay/
Reduction
Yes 16 73
No 25 47 0.0653 1.899 (0.9875–4.053)
Metastasis Yes 31 47
No 10 104 0.0063 2.804 (1.396–5.366)
Previous
Chemotherapy
Yes 12 42
No 29 77 0.0049 2.63 (1.586–10.21)
Tumor
Diameter
≥6.7 cm 21 46.5
<6.7 cm 20 77 0.0147 2.143 (1.219–4.529)
PFS, Progression-free survival; HR, Hazard ratio; 95% CI, 95%
confidence interval; CR, Complete response; PR, Partial response;
SD, Stable disease; PD, Progressive disease.
Fig 1. Kaplan–Meier curve depicting progression-free survival of
dogs whose best response to treatment was either complete
response (CR), partial response (PR), or stable disease (SD)/pro-
gressive disease (PD). P value indicates logrank test for trend
across the 3 groups.
Table 5. Factors evaluated for effects on overall sur-
vival.
Groups n
Median
ST
Logrank
P
Logrank
HR (95% CI)
Response CR/PR 19 168
SD/PD 21 118 0.4962 1.36 (0.5795–3.155)
Delay/
Reduction
Yes 16 222
No 25 114 0.051 2.215 (1.002–4.537)
Metastasis Yes 31 114
No 10 361 0.0759 2.182 (0.9962–4.947)
Previous
Chemotherapy
Yes 12 50
No 29 146 0.0453 2.04 (1.04–5.798)
Tumor
Diameter
≥6.7 cm 21 89
<6.7 cm 20 264 0.0195 2.162 (1.201–5.034)
ST, Survival time; HR, Hazard ratio; 95% CI, 95% confidence
interval; CR, Complete response; PR, Partial response; SD, Stable
disease; PD, Progressive disease.
1102 Burton et al
The adverse gastrointestinal effects observed in this
study were mild to moderate and primarily occurred
after the first dose of lomustine. This observation is in
contrast to what has been reported for chronic TOC
administration, during which up to 46% of dogs experi-
enced some degree of gastrointestinal toxicity.13 One
potential mechanism of gastrointestinal toxicity second-
ary to TOC is the inhibition of the KIT protein on the
interstitial cells of Cajal, resulting in gastrointestinal hy-
pomotility. Pulse administration of TOC may have pre-
vented long-term down-regulation of KIT signaling in
the interstitial cells of Cajal, thereby decreasing gastro-
intestinal toxicity with this dosing schedule.
The ORR of 46% for pulse-administered TOC com-
bined with lomustine is comparable to what previously
has been reported for single-agent protocols,5,7,12,13 but
considerably higher than that reported with single-agent
lomustine in a recent multicenter prospective trial
(23%).34 Although a randomized, prospective clinical
trial would be required to determine if 1 protocol was
superior to the other, combining pulse-administered
TOC with lomustine may be appealing to some pet
owners who do not want to pursue parenteral chemo-
therapy for their pet but also cannot financially commit
to using TOC as monotherapy caused by the cost of the
drug and associated monitoring. Not surprisingly, the
presence of metastatic disease and lack of response to
therapy were associated with a short PFS in multivari-
ate analysis. Dogs that were previously untreated also
had an improved PFS and OS as compared to dogs that
had previously received chemotherapy for MCT. These
findings suggest that although the combination of
pulse-administered TOC and lomustine is efficacious,
the combination may not overcome the MCT drug
resistance that may have occurred in dogs that have
failed other therapies. The presence of a c-kit ITD did
not affect PFS or OS for this group of dogs, nor was it
associated with response to treatment. This finding is in
contrast to a previous publication evaluating TOC
monotherapy for MCT in which c-kit mutation was
associated with a higher likelihood of response,13 and is
in contrast to a study combining TOC and palliative
radiation therapy, in which c-kit mutation was associ-
ated with an inferior outcome.17 This finding highlights
the importance of evaluating prognostic factors such as
c-kit mutation status in a context-specific setting, rather
than extrapolating from previous studies.
In conclusion, lomustine at a dosage of 50 mg/m2
once every 3 weeks combined with pulse-dosed TOC
was well tolerated, but the ORR was not superior to
single-agent protocols. c-kit gene mutation status did
not affect outcome. Notably, pulse administration of
TOC was associated with a relatively low incidence of
adverse gastrointestinal events, when compared with
continuous exposure, and use of a lower dosage of lo-
mustine may have contributed to a lower frequency of
severe hepatotoxicity. A prospective, randomized trial
evaluating whether this combination is advantageous
over either lomustine or TOC alone should be consid-
ered based on these results.
Footnotes
a Qiagen DNEasy Blood and Tissue kit, Qiagen, Valencia, CA
b Phusion Blood Direct PCR kit, Thermo Scientific, Waltham, MA
c ABI Prism 3730xl genetic analyzer, Applied Biosystems, Carls-
bad, CA
d GeneMarker v1.85, SoftGenetics, State College, PA
e Prism v. 6.0b, GraphPad Software, La Jolla, CA
f SPSS v. 21, IBM, Armonk, NY
g Nutramax Laboratories Veterinary Sciences, Inc., Lancaster, SC
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